Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation

–Session Will Focus on Diagnosis of Hematopoietic Stem Cell
Transplant-Associated Thrombotic Microangiopathy–

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced an upcoming
educational event at the 2019 Annual Meeting of the European Society of
Blood and Marrow Transplantation to be held in Frankfurt, Germany on
March 24-27, 2019. Sponsored by Omeros, the educational session entitled
“How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at
2:00-3:30 PM local time. There is growing recognition that hematopoietic
stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a
potentially lethal complication of stem-cell transplants, is
underdiagnosed in the U.S. and worldwide. A study from the Dana Farber
Cancer Institute reported that, while 39% of patients receiving
allogeneic HSCT developed TMA, the disorder was often unrecognized
during clinical care.

The session, conducted by an international panel of experts, will focus
on the diagnosis of HSCT-TMA and on the relationship between HSCT-TMA
and the broader syndrome of disorders caused by endothelial injury. In
addition to TMA, endothelial injury is associated with several
complications of HSCT, including graft-versus-host disease,
veno-occlusive disease, and diffuse alveolar hemorrhage. Narsoplimab,
Omeros’ antibody to inhibit the lectin pathway of complement, has
received breakthrough therapy designation from FDA and is in Phase 3
development for the treatment of HSCT-TMA.